Ventyx Biosciences (NASDAQ:VTYX) Stock Rating Reaffirmed by HC Wainwright

Ventyx Biosciences (NASDAQ:VTYX)‘s stock had its “neutral” rating reaffirmed by equities researchers at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $6.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 143.90% from the stock’s current price.

Several other research firms also recently weighed in on VTYX. Canaccord Genuity Group decreased their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Oppenheimer decreased their target price on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Thursday, June 6th. Finally, Wells Fargo & Company decreased their target price on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Ventyx Biosciences presently has an average rating of “Moderate Buy” and an average price target of $8.29.

Ventyx Biosciences Price Performance

Shares of VTYX opened at $2.46 on Monday. The company has a market cap of $173.43 million, a PE ratio of -0.76 and a beta of 0.37. The business has a fifty day moving average of $2.26 and a 200 day moving average of $3.65. Ventyx Biosciences has a 52-week low of $1.79 and a 52-week high of $36.19.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.12. As a group, research analysts anticipate that Ventyx Biosciences will post -2.14 earnings per share for the current fiscal year.

Institutional Trading of Ventyx Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in VTYX. SG Americas Securities LLC bought a new stake in shares of Ventyx Biosciences in the second quarter valued at about $32,000. The Manufacturers Life Insurance Company grew its stake in Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after purchasing an additional 7,096 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Ventyx Biosciences in the second quarter valued at about $58,000. Norden Group LLC purchased a new position in Ventyx Biosciences in the first quarter valued at about $59,000. Finally, American Century Companies Inc. purchased a new position in Ventyx Biosciences in the second quarter valued at about $60,000. 97.88% of the stock is currently owned by institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.